[Skip to Content]
[Skip to Content Landing]
Views 1,556
Citations 0
News From the Food and Drug Administration
May 19, 2020

Therapy Approved for Hard-to-Treat Upper Tract Urothelial Cancer

JAMA. 2020;323(19):1887. doi:10.1001/jama.2020.7153

The first treatment for low-grade upper tract urothelial cancer (UTUC) has received FDA approval.

Although US health officials were focused on combating coronavirus disease 2019 when mitomycin gel was approved in mid-April, the director of the FDA’s Oncology Center of Excellence said that “patients with cancer and their unique needs continue to be a top priority” for the agency.